Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mohamed, Ahmed A., M.D. | INDIV |
| Amr Amin College of Medicine, University of Sharjah, Sharjah 27272, UAE. | UNKNOWN |
| Ahmed Cordie Endemic Medicine department, Cairo University Hospitals. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. Although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines.
The aim of the current investigation is to identify the anti-cancer potentiality of saffron on hepatocellular carcinoma patients.
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer mortality in the world. Chronic infection with hepatitis B and C is the major risk factors for HCC worldwide. Other factors that contribute to the formation of HCC include exposure to environmental carcinogens, iron overload, fatty liver disease, and alcohol abuse.
there has been a sustained rise in its incidence in both developing and developed countries. Despite the growing therapeutic options for patients with cancer, their efficacy is time-limited and non-curative. Hence to overcome these drawbacks, an incessant screening for superior and safer drugs has been ongoing for numerous decades, resulting in the detection of anti-cancer properties of several phytochemicals. Chemoprevention using readily available natural substances from vegetables, fruits, herbs and spices is one of the significantly important approaches for cancer prevention in the present era. Among the spices, saffron has generated interest because pharmacological experiments have established numerous beneficial properties including radical scavenging, anti-mutagenic and immuno-modulating effects.
Saffron is a naturally derived plant product from the dried stigma of the Crocus sativus flower (family Iridaceae) that may have biologically useful properties. In fact, saffron extract and its biologically active compounds, including crocin, crocetin, carotene, and safranal, have been shown both in vitro and in vivo to possess antioxidant, anticancer, anti-inflammatory, and memory-improving properties. Saffron is also used in folk medicine as an antispasmodic, antidepressant, and aphrodisiac. Furthermore, it is one of the most commonly used species around the world for flavouring and colouring foods.
Saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. Although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| safranal Group | Active Comparator | include 20 HCC patients will receive 50 mg safranal regimen in dose of once per day for six months. |
|
| Control Group | Placebo Comparator | include 20 HCC patients will receive placebo in the form of once per day for six months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Saffranal | Dietary Supplement | HCC patients will receive 50 mg safranal regimen in dose of once per day for six months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| overall survival | overall survival in patients presented with end-stage hepatocellular carcinoma. | three months |
| Measure | Description | Time Frame |
|---|---|---|
| treatment response | response to treatment through impact on the underlying liver status | three months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Amal A. Elkholy | Contact | 01060355448 | amal.elkhouly@pharma.asu.edu.eg |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amal A. Elkholy | Al ‘Abbāsīyah | Al Abbasiya | 123456 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15582266 | Background | Abdullaev FI, Espinosa-Aguirre JJ. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev. 2004;28(6):426-32. doi: 10.1016/j.cdp.2004.09.002. | |
| 11788779 | Background | Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med (Maywood). 2002 Jan;227(1):20-5. doi: 10.1177/153537020222700104. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| Nouran Mohamed Endemic Medicine department, Cairo University Hospitals. | UNKNOWN |
| Misr University for Science and Technology | OTHER |
randomized clinical trial
Not provided
Not provided
Single blinded
| Placebo | Dietary Supplement | HCC patients will receive Placebo in dose of once per day for six months. |
|
| Dermatology Clinic of National Hepatology and Tropical Medicine Research Institute | Cairo | 123456 | Egypt |
| 26151016 | Background | Bhandari PR. Crocus sativus L. (saffron) for cancer chemoprevention: A mini review. J Tradit Complement Med. 2015 Jan 28;5(2):81-7. doi: 10.1016/j.jtcme.2014.10.009. eCollection 2015 Apr. |
| 19328523 | Background | Das I, Das S, Saha T. Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: A histopathological study. Acta Histochem. 2010 Jul;112(4):317-27. doi: 10.1016/j.acthis.2009.02.003. Epub 2009 Mar 27. |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |